文献速递类风湿关节炎

灰阶超声检出的类风湿关节炎滑膜炎可预测未来三年骨侵蚀进展

Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该队列研究嵌套于瑞士RA登记,评估灰阶超声(GSUS)与能量多普勒超声(PDUS)滑膜炎单独或联合(CombUS)预测关节损伤进展。中位随访35个月后,GSUS与CombUS较高水平与X线关节损伤进展显著相关,GSUS是生物制剂治疗患者关节损伤进展的独立预测因素。

要点

  • GSUS和CombUS较高水平与RA关节损伤进展显著相关。
  • GSUS是生物制剂治疗患者关节损伤进展的独立预测因素。
  • 临床疾病活动度指标在该亚组中无显著预后价值。

核心结论

  • 较高水平的GSUS和CombUS与骨侵蚀进展相关。
  • GSUS似乎是滑膜炎评估的必要组成部分,且在生物制剂治疗患者中是关节损伤进展的独立预测因素。

研究设计与样本

  • 研究为嵌套于瑞士RA登记的队列研究,纳入首次超声评估时具有连续手部X线片的患者。
  • 分析双手腕和16个手指关节的半定量GSUS、PDUS和CombUS评分总和(最高54分),并校正基线临床疾病活动度、生物DMARD使用及其他混杂因素。

主要发现

  • 中位35个月后,CombUS组250例中69例(28%)、PDUS组259例中73例(28%)、GSUS组287例中75例(26%)出现关节损伤进展。
  • PDUS超过正常上限(1/54)、GSUS和CombUS分别在50百分位(9/54和10/54)及75百分位(14/54和15/54)时,在粗模型和校正模型中均与ΔXray显著相关。
  • 亚组分析中,GSUS超过14/54和CombUS高于15/54在生物DMARD治疗患者中仍与ΔXray显著相关,而临床疾病活动度指标在该亚组无显著预后价值。

关键数值与推荐

  • PDUS超过正常上限(1/54)与关节损伤进展显著相关。
  • GSUS在50百分位(9/54)和75百分位(14/54)与关节损伤进展显著相关。
  • CombUS在50百分位(10/54)和75百分位(15/54)与关节损伤进展显著相关。
  • GSUS超过14/54和CombUS高于15/54在生物DMARD治疗患者中仍与ΔXray显著相关。

临床怎么用

  • GSUS可作为RA滑膜炎评估的必要组成部分,用于预测关节损伤进展。
  • 对接受生物DMARD治疗的患者,GSUS可提供独立于临床疾病活动度指标的预后信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To evaluate grey scale US (GSUS) and power Doppler US synovitis (PDUS), separately or in combination (CombUS), to predict joint damage progression in RA. METHODS: In this cohort study nested in the Swiss RA register, all patients with sequential hand radiographs at their first US assessment were included. We analysed the summations of semi-quantitative GSUS, PDUS and CombUS assessments of both wrists and 16 finger joints (maximum 54 points) at their upper limit of normal, their 50th, 75th or 87.5th percentiles for the progression of joint damage (ΔXray). We adjusted for clinical disease activity measures at baseline, the use of biological DMARDs and other confounders. RESULTS: After a median of 35 months, 69 of 250 patients with CombUS (28%), 73 of 259 patients with PDUS (28%) and 75 of 287 patients with available GSUS data (26%) demonstrated joint damage progression. PDUS beyond upper limit of normal (1/54), GSUS and CombUS each at their 50th (9/54 and 10/54) and their 75th percentiles (14/54 and 15/54) were significantly associated with ΔXray in crude and adjusted models. In subgroup analyses, GSUS beyond 14/54 and CombUS higher than 15/54 remained significantly associated with ΔXray in patients on biological DMARDs, while clinical disease activity measures had no significant prognostic power in this subgroup. CONCLUSION: Higher levels of GSUS and CombUS are associated with the development of erosions. GSUS appears to be an essential component of synovitis assessment and an independent predictor of joint damage progression in patients on biological DMARDs.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Möller B, Aletaha D, Andor M, et al. Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years. Rheumatology (Oxford). 2020. PMID: 31630207. doi:10.1093/rheumatology/kez460

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。